GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment
January 06 2019 - 7:00AM
Business Wire
- Artificial Intelligence (AI)-powered
applications will help predict how individual patients will respond
to immunotherapies in advance of treatment
- Partnership will enable identification
of appropriate patients for immunotherapy clinical trials and
treatment, reducing unnecessary and expensive trial failures and
speeding up immunotherapy approvals
GE Healthcare and Vanderbilt University Medical Center (VUMC)
today announced a five-year partnership to enable safer and more
precise cancer immunotherapies. Multiple diagnostic tools will be
developed to help predict both the efficacy of an immunotherapy
treatment and its adverse effects for a specific patient before the
therapy is administered. This would allow physicians to better
target immunotherapies to the right patients and avoid potentially
damaging, ineffective and costly courses of treatments.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190106005028/en/
GE Healthcare, Vanderbilt University
Medical Center partner for safer, more precise immunotherapy cancer
treatment (Photo: Business Wire)
Immunotherapies use the immune system to recognize and attack
cancer cells and can be more effective than traditional treatments,
but response rates are often low and side effects can be severe1.
GE Healthcare and VUMC will retrospectively analyze and correlate
the immunotherapy treatment response of thousands of VUMC cancer
patients, with their anonymized demographic, genomic, tumor,
cellular, proteomic and imaging data. They will then develop
AI-powered apps that draw on this data to help physicians identify
the most suitable treatment for each individual patient.
Simultaneously, GE Healthcare and VUMC will develop new
positron-emission tomography (PET) imaging tracers, which together
with the apps, will help physicians to stratify cancer patients for
clinical trials. It currently takes an average of 12 years2 and
costs almost $2bn3 to bring a drug to market. In many cases,
inappropriate patients are recruited to participate in
immunotherapy trials, incurring unnecessary expense and slowing
down approvals of new therapies. It is hoped that the PET tracers
will ultimately also be used to monitor the efficacy of
immunotherapies in everyday practice.
“Immunotherapy offers tremendous promise but given the current
unpredictability of some patients’ reactions to treatments, it is
also associated with increased morbidity and cost. This partnership
provides the opportunity to leverage strengths of both of our
organizations to further personalize cancer care by creating new
tools that allow clinicians to more accurately predict how patients
will respond to a specific therapy,” said Jeff Balser, MD, PhD,
President and Chief Executive Officer, Vanderbilt University
Medical Center and Dean of the Vanderbilt University School of
Medicine.
“GE Healthcare and Vanderbilt will combine their data science,
genomic, imaging and cellular analysis capabilities to help improve
clinical decision making. This partnership is a great example of
the increasing convergence of the tools, technologies and data used
by therapy innovators and healthcare providers,” said Kieran
Murphy, President and Chief Executive Officer, GE Healthcare.
GE Healthcare and the Vanderbilt-Ingram Cancer Center, a
world-renowned stem cell transplant facility, will also collaborate
on methods to improve productivity, efficiency and cost of stem
cell transplant processing operations by automating processes,
digitizing workflows, improving throughput and industrializing
operations.
The first analytics application prototype will be available by
the end of 2019 and the PET tracer proof-of-concept by the end of
2020.
### END ###
About Vanderbilt University Medical Center Vanderbilt
University Medical Center (VUMC) is one of the nation’s leading
academic medical centers and is the largest comprehensive health
system in Tennessee. Its core missions are the delivery of patient
care, performing biomedical research and training future leaders in
health care. VUMC is the recipient of top accolades by the National
Academies, the Magnet Recognition Program, the Leapfrog Group, and
has been named a Top Hospital by Truven Health Analytics 14 times.
In 2018, U.S. News & World Report named VUMC to the ‘Honor
Roll’ of the nation’s top 20 hospitals with 10 nationally-ranked
adult specialty programs. In 2018, U.S. News also named the Monroe
Carell Jr. Children’s Hospital at Vanderbilt among the nation’s
‘Best Children’s Hospitals’ with 10 out of 10 pediatric specialty
programs nationally ranked. For more information and the latest
news follow Vanderbilt Health on Facebook, LinkedIn,
Twitter, and in the VUMC Reporter.
About GE Healthcare GE Healthcare is the $19 billion
healthcare business of GE (NYSE: GE). As a leading provider of
medical imaging, monitoring, biomanufacturing, and cell and gene
therapy technologies, GE Healthcare enables precision health in
diagnostics, therapeutics and monitoring through intelligent
devices, data analytics, applications and services. With over 100
years of experience in the healthcare industry and more than 50,000
employees globally, the company helps improve outcomes more
efficiently for patients, healthcare providers, researchers and
life sciences companies around the world. Follow us
on Facebook, LinkedIn, Twitter and The
Pulse for latest news, or visit our
website www.gehealthcare.com for more information.
These statements are not guarantees of future performance and
undue reliance should not be placed on them.
__________________________ 1
https://www.cancer.net/blog/2018-02/what-you-need-know-about-immunotherapy-side-effects2
https://www.sciencedirect.com/science/article/pii/S2452302X1600036X3
https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/measuring-return-from-pharmaceutical-innovation.html
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190106005028/en/
GE HealthcareDavid MorrisDavid.j.morris@ge.com0044 7920
591370
Vanderbilt University Medical CenterJohn
HowserJohn.Howser@vumc.org001 615-322-4747
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Mar 2024 to Apr 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Apr 2023 to Apr 2024